JOP20250045A1 - تركيبات صيدلانية لمثبطات توبوإيزوميراز- 1 مشتقة من إكساتيكان، واستخداماتها - Google Patents

تركيبات صيدلانية لمثبطات توبوإيزوميراز- 1 مشتقة من إكساتيكان، واستخداماتها

Info

Publication number
JOP20250045A1
JOP20250045A1 JOJO/P/2025/0045A JOP20250045A JOP20250045A1 JO P20250045 A1 JOP20250045 A1 JO P20250045A1 JO P20250045 A JOP20250045 A JO P20250045A JO P20250045 A1 JOP20250045 A1 JO P20250045A1
Authority
JO
Jordan
Prior art keywords
exatecan
pharmaceutical formulations
topoisomerase
inhibitors derived
disclosure
Prior art date
Application number
JOJO/P/2025/0045A
Other languages
English (en)
Inventor
V Quiroz Ryan
Elizabeth Johnson Rebecca
Yang Song
B Lang Simon
BACAUANU Vlad
B Charati Manoj
S Zepeda Nancy
Michael Seganish W
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of JOP20250045A1 publication Critical patent/JOP20250045A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الكشف الحالي بالكحول والأمين المحتوي على مشتقات إكساتيكان، والأملاح المقبولة صيدلانيًا أو ذواباتها، تشتمل بنية الصيغة I على ما يلي: ( صورة الصيغة (I) ) حيث تم تحديد X في الكشف. يتعلق الكشف أيضًا بتركيبات صيدلانية تشتمل على هذه المركبات واستخدام هذه المركبات والتركيبات في الوقاية أو العلاج من أمراض السرطان و/أو الأورام.
JOJO/P/2025/0045A 2022-09-02 2025-02-24 تركيبات صيدلانية لمثبطات توبوإيزوميراز- 1 مشتقة من إكساتيكان، واستخداماتها JOP20250045A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263403515P 2022-09-02 2022-09-02
US202263421844P 2022-11-02 2022-11-02
US202363488007P 2023-03-02 2023-03-02
PCT/US2023/031582 WO2024049931A1 (en) 2022-09-02 2023-08-31 Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof

Publications (1)

Publication Number Publication Date
JOP20250045A1 true JOP20250045A1 (ar) 2025-02-24

Family

ID=88241506

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0045A JOP20250045A1 (ar) 2022-09-02 2025-02-24 تركيبات صيدلانية لمثبطات توبوإيزوميراز- 1 مشتقة من إكساتيكان، واستخداماتها

Country Status (18)

Country Link
US (1) US20240116945A1 (ar)
EP (1) EP4581035A1 (ar)
JP (2) JP2025511436A (ar)
KR (1) KR20250053961A (ar)
CN (1) CN120225528A (ar)
AU (1) AU2023336062A1 (ar)
CA (1) CA3265870A1 (ar)
CL (1) CL2025000536A1 (ar)
CO (1) CO2025002460A2 (ar)
CR (1) CR20250070A (ar)
DO (1) DOP2025000046A (ar)
GE (1) GEAP202516720A (ar)
IL (1) IL319241A (ar)
JO (1) JOP20250045A1 (ar)
MX (1) MX2025002491A (ar)
PE (1) PE20251401A1 (ar)
TW (1) TW202423928A (ar)
WO (1) WO2024049931A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN117417347A (zh) * 2023-09-28 2024-01-19 杭州爱科瑞思生物医药有限公司 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用
CN121226387A (zh) * 2024-06-27 2025-12-30 鲁南新时代生物技术有限公司 一种喜树碱衍生物及其制备

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378110B (ar) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (ar) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5173503A (en) * 1989-11-15 1992-12-22 Schering Agrochemicals Limited Imidazole fungicides
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO2001070677A1 (en) 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
CA2427206C (en) 2000-11-02 2011-06-28 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
JP3711131B2 (ja) 2001-08-21 2005-10-26 メルク シャープ エンド ドーム リミテッド 新規のシクロヘキシルスルホン
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
EP1503998B1 (en) 2002-05-01 2009-07-01 MERCK SHARP & DOHME LTD. Heteroaryl substituted spirocyclic sufamides for inhibition of gamma secretase
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
MXPA05012323A (es) 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
US7514459B2 (en) 2003-09-24 2009-04-07 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
UA94628C2 (ru) 2006-10-27 2011-05-25 Дженентек, Инк. Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение
CN102802840B (zh) 2010-01-20 2014-10-29 麦格纳国际公司 双金属部件及其制造方法
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
DE102012219966A1 (de) * 2012-10-31 2014-04-30 Krones Ag Bereitstellen entgasten Wassers
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
WO2016127790A1 (zh) 2015-02-15 2016-08-18 江苏恒瑞医药股份有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
US20230054458A1 (en) * 2019-12-12 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
JP2023551355A (ja) * 2020-09-30 2023-12-08 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド 抗腫瘍化合物並びにその調製方法及び使用
JP7753372B2 (ja) * 2020-10-12 2025-10-14 シーチュアン バイリ ファーム シーオー． エルティーディー 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
GEAP202416409A (en) * 2021-05-07 2024-02-26 Alx Oncology Inc Exatecan derivatives and antibody-drug conjugates thereof
CN115850291B (zh) * 2021-09-24 2024-11-15 石药集团巨石生物制药有限公司 喜树碱衍生物及其用途
IL313805A (en) * 2021-12-28 2024-08-01 Beigene Switzerland Gmbh Drug antibody conjugates

Also Published As

Publication number Publication date
CN120225528A (zh) 2025-06-27
US20240116945A1 (en) 2024-04-11
GEAP202516720A (en) 2025-07-10
JP2026035660A (ja) 2026-03-04
CR20250070A (es) 2025-04-10
WO2024049931A1 (en) 2024-03-07
CO2025002460A2 (es) 2025-03-17
CA3265870A1 (en) 2024-03-07
CL2025000536A1 (es) 2025-06-27
JP2025511436A (ja) 2025-04-16
IL319241A (en) 2025-04-01
EP4581035A1 (en) 2025-07-09
MX2025002491A (es) 2025-04-02
AU2023336062A1 (en) 2025-03-13
KR20250053961A (ko) 2025-04-22
PE20251401A1 (es) 2025-05-22
DOP2025000046A (es) 2025-04-15
TW202423928A (zh) 2024-06-16

Similar Documents

Publication Publication Date Title
JOP20250045A1 (ar) تركيبات صيدلانية لمثبطات توبوإيزوميراز- 1 مشتقة من إكساتيكان، واستخداماتها
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
JOP20220271A1 (ar) مركبات دايازينو بيريميدين كمثبطات لـ her2
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
JOP20210172A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
NZ793536A (en) Imidazolidinone derivatives and medical use thereof
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ZA202400988B (en) Aak1 inhibitor and use thereof
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
JOP20250090A1 (ar) حمولات وصلة adc مشتقة من إكساتيكان، تركيبات صيدلانية، واستخداماتها